AHA 2026 at a glance
The AHA Scientific Sessions 2026 will highlight developments in cardiovascular research, emerging therapies and artificial intelligence that could influence treatment targets and competitive strategy.
From pelacarsen and ziltivekimab outcomes to genetic medicine and AI diagnostics, LucidQuest is watching the clinical evidence and industry signals that could shape the next phase of cardiovascular care.
📅 Build your schedule around the sessions that matter most.
📥 Download the AHA_2026_Preview_by_LucidQuest
Key Scientific and Strategic Themes at AHA 2026
Lp(a) Outcomes: Pelacarsen and Lipoprotein(a) Treatment
Pelacarsen’s Lp(a) HORIZON results could reshape treatment strategies, reimbursement expectations and the competitive positioning of emerging siRNA therapies.
Inflammation: Ziltivekimab and IL-6 Inhibition
Ziltivekimab’s ZEUS outcomes will test IL-6 inhibition, potentially creating new opportunities for biomarker-guided cardiovascular treatment.
Genetic Medicine: ANGPTL3 CRISPR Editing and AAV
ANGPTL3 CRISPR editing and early AAV findings will raise critical questions around durability, patient selection and payer acceptance.
Cardiometabolic Outcomes: Organ-Specific Benefits
Incretin competition is shifting toward organ-specific benefits across heart failure, sleep apnoea and kidney disease.
Competitor and Industry Signals
Novo Nordisk: Inflammatory and Metabolic Risk Management
Ziltivekimab and GLP-1 programmes may bring inflammatory and metabolic risk management closer together.
Sirius Therapeutics and Rona Therapeutics: Lp(a) Treatment Competition
Once-yearly Lp(a) silencing and dual PCSK9/Lp(a) targeting signal emerging competition around dosing and efficacy.
Alnylam Pharmaceuticals, AstraZeneca and Ionis Pharmaceuticals: ATTR-CM Treatment Differentiation
New ATTR-CM analyses will inform differentiation through earlier detection, monitoring and treatment sequencing.
Artificial Intelligence and Machine Learning at AHA Scientific Sessions 2026
AI Diagnostics: Smartwatch ECG, Tele-ECG and AI-Assisted Echocardiography
Smartwatch ECG, tele-ECG and AI-assisted echocardiography will face randomised or external validation.
Cardiovascular Foundation Models: Generalisability and Clinical Integration
Cardiovascular imaging models will bring generalisability, clinical integration and governance into sharper focus.
What We Are Watching After AHA 2026
- Whether Lp(a) and inflammation outcomes support new reimbursed treatment pathways.
- Whether one-time genetic interventions demonstrate sufficient durability for chronic cardiovascular disease.
- Whether validated AI diagnostics progress from research into routine clinical adoption.
Download the AHA Scientific Sessions 2026 Preview Report
Which cardiovascular developments could reshape treatment strategies and competitive positioning at AHA 2026? Download LucidQuest’s preview report to explore the key clinical developments, emerging therapies and industry signals we are watching ahead of the conference.
📅 Build your schedule around the sessions that matter most.
📥 Download the AHA_2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
